Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio reported additional Phase 1a/b data for PALI-2108 showing colon-targeted exposure and sustained IC90 coverage supporting once-daily dosing in ulcerative colitis. The analysis demonstrated significant biomarker improvements including approximately 70% reduction in fecal calprotectin and 58% reduction in Nancy score, with pre-dose trough concentrations exceeding the IC90 threshold.
Key figures
- Drug Name
- PALI-2108
- Phase Of Trial
- Phase 1a/b
- Camp increase
- ~27%
- Tissue plasma ratio
- 6-fold
- Lymphocyte reduction
- ~30–40%
- Nancy score reduction
- −58%
- Clinical response rate
- 100%
- Geboes score reduction
- −36%
- Clinical remission rate
- 40%
- Robarts index reduction
- −56%
- Trough vs cmax increase
- approximately 20%
- Pde4b expression reduction
- ~71%
- Fecal calprotectin reduction
- ~70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.